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SUMMARY
Objective: Angiogenesis is essential for tumor growth and metastasis. Angiogenesis regulators, which are
controlled by ovarian hormones, play an important role during endometrial carcinogenesis. The study evaluated
the relationship between angiogenesis and clinicopathologic parameters, and the possible regulatory roles of
estrogen receptor (ER) and progesterone receptor (PR) status in the angiogenesis of endometrial carcinoma.
Materials and Methods: Twenty patients undergoing surgery for endometrial carcinoma were enrolled. The
microvessel density (MVD) of the excised tumor was assessed immunohistochemically. The relationships between
the tumor MVD (MVD-T) and tumor/normal counterpart MVD ratio (MVD T/N ratio) and clinicopathologic
parameters, including histologic grade, myometrial invasion, cervical involvement, lymph node involvement,
lymphovascular space involvement, menopausal status, histologic type, stage, and ER and PR status, were
analyzed.
Results: The relationships between MVD (= 200 fields) and clinicopathologic parameters were not significantly
different in the 20 patients when only tumor lesions were counted. However, several clinicopathologic parameters
were significantly different when MVD was measured as the T/N ratio. The MVD T/N ratios were significantly
higher in tumors of histologic grades 2 and 3, with lymphovascular space involvement, and of serous type,
when compared, respectively, with tumors of histologic grade 1 (1.31 vs 1.07, p = 0.010), with no lymphovascular
space involvement (1.32 vs 1.13, p = 0.029), and of endometrioid type (1.48 vs 1.13, p = 0.021). MVD
T/N ratios were higher in ER-negative, PR-negative and both receptor-negative tumors compared with ER-
positive, PR-positive and both receptor-positive tumors (1.33 vs 1.02, p = 0.002).
Conclusions: There was a better correlation between MVD T/N ratios and clinicopathologic parameters, even
taking into account the inborn heterogeneity characteristics of endometrial cancer and the limited case number.
Anti-angiogenesis factors may have a close relationship with ovarian hormone receptor status in the different
pathogeneses of endometrial carcinoma. [Taiwanese J Obstet Gynecol 2004;43(4):199–205]
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Introduction
Endometrial cancer is the most common gynecologic
malignancy in the Western world, and the second most
common in Taiwan. The estimated incidence increases
in more industrialized countries, so endometrial cancer
will play an increasingly important role in gynecologic
malignancies in the next decades. The clinical course
and prognosis of endometrial cancer are mainly asso-
ciated with tumor stage, histologic subtype and grade,
age, and hormone receptor status [1]. Clinical and
pathologic evidence for endometrial carcinoma have
led to the development of two classifications: type I
(estrogen-related) and type II (non-estrogen-related)
[2]. Type I is found in relatively young, perimenopausal
women with an estrogen-related risk history and a his-
tory of endometrial hyperplasia [2]. In contrast, type II
is seen in older, postmenopausal women with no
estrogen-related risk history and is not preceded or ac-
companied by hyperplasia [2,3]. Angiogenesis status
and/or angiogenic regulators related to the different
pathogeneses of endometrial carcinomas, especially in
the highly variable expression of microvessel density
(MVD), are not known.
Angiogenesis, the formation of new capillaries from
pre-existing blood vessels, is a physiologic process in
adult cyclic endometrial changes [4], which are highly
controlled processes mediated by angiogenic and anti-
angiogenic factors, under the direct or indirect influence
of ovarian hormones [5]. Angiogenesis is also important
for disease processes including dysfunctional uterine
bleeding, response to exogenous hormonal treatment,
bleeding associated with intrauterine contraceptive
devices, uterine leiomyomata, endometriosis, complex
endometrial hyperplasia and endometrial carcinoma
[6]. Tumor angiogenesis is essential for tumor growth
and metastasis [7]. In order to grow beyond minimal
size and to metastasize, tumors need to induce the
growth of new blood vessels. Intratumoral angiogene-
sis status (measured by MVD) has been proposed as
a prognostic factor in endometrial carcinoma [7–10],
as have angiogenic factors (e.g. vascular endothelial
growth factor [VEGF]) and anti-angiogenic factors (e.g.
thrombospondin-1 [TSP-1]) [10,11]. Down-regulation
of angiogenesis inhibitors plays a critical role in the
angiogenic switch in several tumor types, including
bladder cancer, breast cancer, glioblastoma and fibro-
sarcoma [12–14]. We found that MVD in normal cervi-
cal epithelia and low-grade squamous intraepithelial
lesions (LSIL) were significantly lower than those in
high-grade squamous intraepithelial lesions (HSIL)
and squamous cell carcinoma [15]. MVD is negatively
associated with the expression of the angiogenesis
inhibitor TSP-1. Down-regulation of an angiogenesis
inhibitor and the switch to the angiogenic phenotype
occurs during the transition from LSIL to HSIL [15].
The aim of this study was to correlate angiogenesis
status, as measured using the MVD of the tumor alone
(MVD-T) or the tumor/normal counterpart MVD ratio
(MVD T/N ratio), with the clinicopathologic parameters
of endometrial carcinoma with innate highly variable
expression of MVD. We also tried to understand the re-
lationship between estrogen receptor (ER) and proges-
terone receptor (PR) status and angiogenesis, because
angiogenesis regulators are controlled by progester-
one and estrogen [5].
Materials and Methods
From July 2000 to June 2002, patients in the Department
of Obstetrics and Gynecology of Chi Mei Foundation
Hospital with endometrial carcinoma were recruited
into this study. All patients underwent total abdominal
hysterectomy, bilateral salpingo-oophorectomy and
pelvic and/or para-aortic lymph node dissection or sam-
pling. Patients with lymph node metastasis or deep
myometrial invasion (more than one-half depth) also
received postoperative adjuvant irradiation. Stage
was determined using the International Federation of
Gynecology and Obstetrics classification [16]. Patients
with tumors of histologic types other than adenocar-
cinoma and adenoacanthoma were excluded. Histo-
logic grade used a three-level system: grade 1 (> 95%
glandular formation), grade 2 (5–50% solid growth
pattern) and grade 3 (> 50% solid pattern). Other clini-
copathologic parameters including myometrial inva-
sion, cervical involvement, lymph node metastasis, me-
nopausal status, histologic type, and ER and PR status
were recorded.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissue blocks were
cut into serial sections of 4 +m thickness. One section
from each sample was stained with hematoxylin and
eosin to confirm the histologic diagnosis, and adjacent
sections were stained with anti-CD34 antibody (1:50;
Serotec, Raleigh, NC, USA), ER and PR antibodies (1:30;
Novocastra, Newcastle-upon-Tyne, UK) using standard
immunoperoxidase methods. Slides were incubated with
the BioGenex supersensitive immunodetection system
(San Ramon, CA, USA). Diaminobenzidin tetrahydro-
chloride was used as the chromogen. Human placenta,
which expresses CD-34, was used as the positive con-
trol. A negative control, in which the primary antibody
was substituted with the same concentration of the
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appropriate immunoglobulin G (IgG), was included in
each staining run. All slides were reviewed by a pathol-
ogist (CCT) and associates, who were blinded to the
patients’ status.
Microvessel density
Microscopic sections were scanned at low magnification
(= 40) to identify areas with a high density of capillaries.
Using anti-CD34 antibody immunostaining to highlight
endothelial cells, MVD was determined by counting the
number of vessels in a = 100 field (= 10 objective lens
and = 10 ocular lens, approximately 0.29 mm2/field).
The number of vessels per field was calculated by aver-
aging the total number obtained from six fields in two
different blocks for each tumor. Vessels were defined
as any positively stained single cell or cluster of cells.
Both tumor and normal tissue were counted for com-
parison. The MVD T/N ratio was defined as the ratio
of MVD of tumor lesions and normal counterparts
obtained in two high-power-fields from the tumor
lesion site from the same patient. The relationships
among MVD-T, MVD T/N ratio and clinicopathologic
parameters were analyzed.
Statistical analysis
All values are reported as mean ( standard deviation
(SD). Due to the small sample size and ordinal property
of some parameters, the MVD and MVD T/N ratio were
subjected to non-parametric data analysis. The Wilcoxon
rank sum test was used to evaluate the significance be-
tween different subgroups. A p value of less than 0.05
was considered statistically significant.
Results
The mean age of the 20 women was 54.5 years with a SD
of 10.8 years. The tumor MVD was 46.8, the MVD of the
normal counterpart was 39.9, giving an MVD T/N ra-
tio of 1.17 (Table 1). Most cases (60%) were histologic
grade 1, most (70%) had myometrium invasion of less
than one-half, and most (95%) had no cervical involve-
ment (Table 2). Lymph node metastasis was absent
in nine cases (45%) and present in four (20%); no data
were available for seven cases (35%). Most patients
(80%) did not have lymphovascular space involvement.
Seven patients (35%) were premenopausal and 13 (65%)
were postmenopausal. Most patients (90%) had endo-
metrioid tumor and most (65%) had surgicopathologic
stage Ib disease. The distributions of ER and PR status
were similar (Table 2).
Table 1. Microvessel densities (MVDs) of the tumor
(MVD-T) and the ratio of the tumor and normal
counterpart MVD ratio (MVD T/N ratio)
Variable Mean ( SD
Age 54.5 ( 10.8
MVD-T 46.8 ( 18.7
MVD-N 39.9 ( 14.3
MVD T/N ratio 1.17 ( 0.21
SD = standard deviation; N = normal counterpart.
Table 2. Clinicopathologic parameters among the
20 patients
n (%)
Histologic grade
1 12 (60)
2 3 (15)
3 5 (25)
Myometrial invasion
– 1 (5)
< 1/2 14 (70)
* 1/2 5 (25)
Cervical involvement
– 19 (95)
+ 1 (5)
Lymph node involvement
– 9 (45)
+ 4 (20)
N/A 7 (35)
Lymphovascular space involvement
– 16 (80)
+ 4 (20)
Menopausal status
Pre 7 (35)
Post 13 (65)
Type
Endometrioid 18 (90)
Serous 2 (10)
Stage
Ia 1 (5)
Ib 13 (65)
Ic 1 (5)
II 3 (15)
III 2 (10)
ER
+ 9 (45)
– 11 (55)
PR
+ 9 (45)
– 11 (55)
ER, PR
+, + 7 (35)
–, – 9 (45)
(+, –) or (–, +) 4 (20)
– = negative; + = positive; N/A = not available; ER = estrogen receptor;
PR = progesterone receptor.
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MVD and clinicopathologic parameters
The relationship between MVD and clinicopathologic
parameters is shown in Table 3. There was no signifi-
cant relationship between MVD-T (= 200 field) and any
clinicopathologic parameter. However, the MVD T/N
ratio was significantly higher in tumors of higher histo-
logic grade (grade 2 and 3; p = 0.010), with lympho-
vascular space involvement (p = 0.029) and of serous
type (p = 0.021), compared with tumors of histologic
grade 1, without lymphovascular space involvement
and of endometrioid type. The MVD T/N ratio was high-
er in ER-negative (p = 0.002), PR-negative (p = 0.016)
and both receptor-negative tumors (p = 0.002) compared
with ER-positive, PR-positive and both receptor-positive
tumors.
Characteristic pictures are shown in the Figure. Mi-
crovessels were much less common in endometrioid
tumors (Figure 1A) than in serous tumors (Figure 1B).
Most endometrioid tumors were PR-positive (Figure 1C)
while both serous tumors were PR-negative (Figure 1D).
Discussion
MVD counting techniques have been widely used to
assess the vasculature in tumors. MVD counts assess
the presence of blood vessels but do not give an indica-
tion of the degree of angiogenesis and the functional sta-
tus of the tumor neovasculature [17]. MVD has been re-
ported to be associated with unfavorable histopatho-
logic features, or as a predictor of tumor progression
or metastasis [18,19]. However, we did not see any dif-
Table 3. Correlation of clinicopathologic parameters and microvessel density (MVD)
MVD-T T/N ratio
N
Mean ( SD p Mean ( SD p
Histologic grade
1 12 40.3 ( 15.9 0.057 1.07 ( 0.19 0.010
2/3 8 56.6 ( 19.3 1.31 ( 0.18
Myometrial invasion
< 1/2 15 45.5 ( 20.1 0.349 1.16 ( 0.18 0.933
* 1/2 5 50.8 ( 14.9 1.18 ( 0.32
Lymph node involvement
– 9 49.3 ( 25.3 0.710 1.13 ( 0.20 0.604
+ 4 52.3 ( 16.8 1.23 ( 0.35
Lymphovascular space involvement
– 16 42.7 ( 15.6 0.099 1.13 ( 0.22 0.029
+ 4 63.5 ( 23.1 1.32 ( 0.06
Menopausal status
Pre 7 38.2 ( 7.8 0.157 1.09 ( 0.18 0.183
Post 13 51.5 ( 21.4 1.21 ( 0.22
Type
Endometrioid 18 45.4 ( 19.2 0.211 1.13 ( 0.19 0.021
Serous 2 59.6 ( 4.9 1.48 ( 0.15
Stage
I 15 46.0 ( 20.0 0.612 1.14 ( 0.18 0.349
> I 5 49.4 ( 16.0 1.24 ( 0.31
ER
– 11 50.8 ( 18.7 0.370 1.30 ( 0.13 0.002
+ 9 42.0 ( 18.5 1.01 ( 0.18
PR
– 11 49.3 ( 20.1 0.710 1.26 ( 0.21 0.016
+ 9 43.9 ( 17.6 1.05 ( 0.17
ER, PR
+, + 7 45.4 ( 19.9 0.606 1.02 ( 0.17 0.002
–, – 9 53.5 ( 19.7 1.33 ( 0.13
T = tumor; T/N ratio = tumor/normal counterpart ratio; SD = standard deviation; – = negative; + = positive; ER = estrogen receptor; PR = progesterone
receptor. Wilcoxon rank sum test was used to evaluate the correlation of clinicopathologic findings and MVD, or MVD T/N ratio.
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ference among our patients. This may be because of
the inborn heterogeneity in endometrial cancer and
the limited case numbers. Highly variable expression of
MVD in different surgical specimens is not uncommon
[20]. In this situation, some novel techniques and meth-
ods can be used to adjust for highly variable angiogen-
esis. Recently, color Doppler ultrasound has been used
as an in vivo model to correlate histologic and biologic
findings with angiogenesis status [21]. In the MVD T/N
ratio measurement system, the normal counterpart can
be used as an internal control to adjust for inborn varia-
tion. We found that MVD T/N ratios were significantly
related to clinicopathologic parameters including histo-
logic grade, lymphovascular space involvement, histo-
logic type and ER and PR status, and were better predic-
tors of clinicopathologic parameters in endometrial
cancer than MVDs of tumor lesions only.
The timing of the angiogenic switch during endo-
metrial carcinogenesis remains unknown. In this study,
MVD T/N ratios were significantly higher in tumors of
high histologic grades (grade 2 and 3) than of low grade
(grade 1). Thus, we postulate that the angiogenic switch
happens during the transition from grade 1 to higher
grades. Angiogenesis is a critical factor in the progres-
sion of many solid tumors. In many cancer models, the
angiogenic switch occurs some time during tumorigene-
sis [22]. When enough tumor cells become angiogenic,
the tumor can expand progressively and shed metasta-
tic cells. This angiogenic switch has recently been quan-
tified for human breast cancer, as well as for prostate
cancer [23]. In cervical multi-step carcinogenesis, MVD
is significantly higher in more advanced lesions (CIN
III) than low-grade lesions (condyloma and CIN I) [24].
This means that the angiogenic switch in cervical car-
cinogenesis occurs during the transition from LSIL to
HSIL [15]. The angiogenic switch during endometrial
carcinogenesis may manifest in a similar pattern.
Lymphovascular space involvement was significantly
associated with MVD, which is compatible with the phe-
nomenon that the degradation of extracellular matrix
is a crucial step in angiogenesis [25]. Iurlaro et al evalu-
ated MVD and matrix metalloproteinase-2 (MMP-2,
gelatinase A) and MMP-9 (gelatinase B) mRNA using
immunohistochemistry and in situ hybridization. Angio-
genesis and extracellular matrix degradation occurred
simultaneously with endometrial upgrading and advanc-
ing depth of invasion [26]. The changes in angiogene-
sis and expression of extracellular matrix-degrading en-
zymes were substantiated during tumor changeover and
progression.
Endometrioid and serous cancers have different un-
derlying pathogenesis, usually either estrogen-related
(endometrioid) or non-estrogen-related (serous) [2].
Estrogen dependency in uterine endometrial cancers
involves complicated tumor biology [27]. Our MVD
T/N ratio results may explain, at least in part, the differ-
ent pathogenesis.
Angiogenesis is regulated by angiogenesis activa-
tors such as VEGF and angiogenesis inhibitors such
as thrombospondins, which are under the control of the
ovarian hormones estrogen and progesterone [5,28].
Both angiogenic and anti-angiogenic factors are respon-
sible for angiogenic balance [29]. Angiogenesis regu-
lators (e.g. TSP-1) may affect the behavior of endometrial
cancer, e.g. cervical and lymphovascular space involve-
ment, and are associated with an angiogenic phenotype
and a prognostic marker in endometrial cancer [30].
The expression of angiogenesis regulators is controlled
by progesterone [5]. The production of TSP-1 at later
stages of the endometrial cycle is linked to the inhibition
of vessel formation and is progesterone-dependent in
this tissue [5]. VEGF can be up-regulated by estrogen
and down-regulated by progesterone [28]. The expres-
sion of VEGF is involved in the promotion of angiogenesis
in endometrial cancer. In addition, VEGF contributes to
the aggressive potential of high-grade tumors or certain
histologic subtypes with unfavorable prognosis through
the induction of angiogenesis [31]. A high level of ER-_
is believed to be favorable in the prognosis and treatment
of certain female cancers [32]. Unlike estradiol, high
levels of ER-_ significantly inhibit the growth of tumors
xenografted from endometrial cancer cells, because of
its inhibitory effect on angiogenic pathways [32].
In conclusion, to know specific angiogenic patterns
Figure. Representative immunohistochemistry staining showing
microvessel density (MVD) and progesterone receptor (PR)
status of endometrioid (A, C) and serous endometrial cancer
(B, D). Note the low tumor/normal counterpart MVD ratio
(MVD T/N ratio) in endometrioid (A) and the high MVD T/N
ratio in serous endometrial cancer (B). Endometrioid endo-
metrial cancer is positive for PR (C) while serous endometrial
cancer is negative for PR (D). (A, B = 100; C, D = 200.)
A B
C D
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of various disease processes might improve anti-
angiogenic medications in therapies for benign and neo-
plastic diseases of the endometrium [6].
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